从最新研究证据重新思上考β-受体阻滞剂在降压治疗中的地位.pptVIP

从最新研究证据重新思考b-受体阻滞剂在降压治疗中的地位 河北省人民医院 郭艺芳 Lindholm荟萃分析主要结果 Lindholm荟萃分析主要结论 Only minimal evidence suggests β-blockers reduce the morbidity and mortality associated with hypertension, especially among the elderly. Clinicians must be sceptical of using drugs for which only surrogate marker evidence is available. All patients 60 and older who are taking β-blockers for hypertension alone should be reassessed because β-blockers are not in a class of agents that reduces morbidity and mortality. Even among patients younger than 60, β-blockers should not be first-line agents. The NICE Hypertension Gu